Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Novo Nordisk A/S]Follow[Vivtex Corporation]FollowFeb 25 (Reuters) - Danish drugma ...

Core Viewpoint - The phase 2 trial results of UBT251, a triple agonist for GLP-1, GIP, and glucagon receptors, indicate significant weight loss and safety in Chinese patients with obesity or overweight, marking a milestone for United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S in their collaboration [1][3][5]. Group 1: Trial Results - UBT251 demonstrated a mean weight loss of 19.7% (-17.5 kg) in the treatment group compared to 2.0% (-1.6 kg) in the placebo group after 24 weeks [3][9]. - Statistically significant improvements were observed in secondary endpoints, including waist circumference, blood glucose, blood pressure, and lipids [4][9]. - The trial involved 205 Chinese patients with a baseline mean body weight of 92.2 kg and a mean BMI of 33.1 kg/m² [7]. Group 2: Development and Future Plans - United Biotechnology plans to initiate a phase 3 trial in Chinese patients based on the phase 2 results [6]. - Novo Nordisk has started a global phase 1b/2a trial with UBT251, expecting topline data in 2027, and plans to initiate a phase 2 trial for type 2 diabetes in the second half of 2026 [5][6]. Group 3: Company Background - TUL is a leading integrated pharmaceutical company in China, focusing on the research and development of pharmaceuticals, with a strong presence in nearly 80 countries [12]. - Novo Nordisk is a global healthcare leader founded in 1923, dedicated to combating chronic diseases, particularly diabetes, and operates in around 170 countries [13].

Core Viewpoint - The conference call is hosted by Novo Nordisk, indicating a focus on investor relations and company performance updates [1] Group 1 - The call is being recorded, suggesting that the information shared will be available for future reference [1] - Michael Novod, the Head of Investor Relations, is the first speaker, highlighting the importance of investor communication in the company's strategy [1]

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Novo Nordisk slump wipes out last Wegovy-era gains after trial setback February 23, 202611:43 AM UTCUpdated ago By Reuters The logo of pharmaceutical company Novo Nordisk is displayed on a flag in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little Purchase Licensing Rights, opens new tab Feb 23 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab shares ...

Data from the U.S. Department of Commerce released on Friday showed that the core PCE price index, a key inflation gauge monitored by the Fed, rose +0.4% m/m and +3.0% y/y in December, stronger than expectations of +0.3% m/m and +2.9% y/y. Also, the U.S. Bureau of Economic Analysis, in its initial estimate of Q4 GDP growth, said the economy grew at a +1.4% annualized rate, weaker than expectations of +2.8%. In addition, U.S. December personal spending rose +0.4% m/m, in line with expectations, and personal ...

The consensus price target for VTVT has increased to $53.50, indicating growing optimism.Recent upgrade to a Zacks Rank #2 (Buy) reflects increased confidence in the company's earnings potential.Strategic partnerships and advancements in clinical trials for TTP399 and HPP737 are key drivers of positive outlook.vTv Therapeutics Inc. (NASDAQ:VTVT) is a clinical-stage biopharmaceutical company that focuses on developing oral treatments for diabetes and other diseases. The company is advancing several promising ...

Group 1 - Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira to its board of directors, marking the first additions since a significant management shake-up in 2025 [1] - The company replaced its CEO and overhauled the board, appointing Lars Rebien Sorensen as board chairman, who also chairs the Novo Nordisk Foundation, consolidating power in a dual role [1] - Jan van de Winkel is the co-founder and CEO of Genmab, while Ramona Sequeira previously served as President of the Global Portfolio Division at Takeda Pharmaceutical Company Limited from 2022 to 2025 [1]

Core Viewpoint - Veru Inc. is advancing its clinical programs for innovative treatments targeting cardiometabolic and inflammatory diseases, with a focus on the upcoming presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1] Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company dedicated to developing innovative medicines for cardiometabolic and inflammatory diseases [3] - The company's drug development pipeline includes two late-stage novel small molecules: enobosarm and sabizabulin [3] Enobosarm Obesity Program - Enobosarm is being developed as a next-generation drug to enhance weight reduction when combined with GLP-1 RA drugs, aiming for more selective fat loss while preserving lean mass [4] - The Phase 2b QUALITY clinical study demonstrated that enobosarm, when used with semaglutide, led to greater fat loss while preserving lean mass and physical function in older patients [4] - The study involved 168 older patients (≥60 years) and showed that while weight loss was similar across treatment groups, the preservation of lean mass is expected to lead to increased energy expenditure and further weight reduction in longer studies [4] Planned Phase 2b PLATEAU Clinical Study - The upcoming Phase 2b PLATEAU clinical trial will evaluate the effects of enobosarm 3 mg on various health metrics in approximately 200 older patients (age ≥ 65) with obesity [5] - The primary efficacy endpoint is the percent change in total body weight at 68 weeks, with an interim analysis planned at 34 weeks [5] - The study aims to assess the ability of enobosarm to overcome weight loss plateaus in patients receiving GLP-1 RA treatment, with a focus on preserving muscle mass and physical function [6]

EU approves higher dose of Novo's Wegovy | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Novo Nordisk A/S]FollowFeb 17 (Reuters) - The European Commission has approved a higher dose of Novo Nordisk's [(NOVOb.CO), opens new tab] popular weight- ...

Core Viewpoint - Hedge funds have significantly increased their short positions against Hims & Hers Health, coinciding with the company's recent challenges related to its weight-loss pill and legal issues with Novo Nordisk [1]. Group 1: Hedge Fund Activity - Hedge fund bets against Hims & Hers Health reached their highest level in at least a year in January, with nearly 65% of available Hims stock loaned out for short selling, the highest since October 2025 [1]. - Short interest in Hims stock hit a record high on February 12, indicating a strong bearish sentiment among investors [1]. Group 2: Company Developments - Hims & Hers Health withdrew its low-cost weight-loss pill under scrutiny from the U.S. Food and Drug Administration (FDA) and faced lawsuits from Novo Nordisk, resulting in a 33% drop in its share price within a week [1]. - The company unveiled a compounded version of Novo Nordisk's Wegovy weight-loss pill on February 5 but retracted it two days later after the FDA's warning against "illegal copycat drugs" [1]. Group 3: Market Implications - The dissolution of the partnership between Hims and Novo Nordisk has led to increased scrutiny and volatility in Hims' stock, prompting hedge funds to take short positions [1]. - Analysts suggest that without access to a branded weight-loss drug, Hims may struggle to compete in the weight-loss market [1].